BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal

BioMarin announces $4.8 billion acquisition of Amicus Therapeutics, adding rare disease treatments Galafold and Pombiliti to its portfolio with expected close in Q2 2026.